Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine is a promising biopharmaceutical company with multiple potential sources of upside, including their pipeline candidate DISC-3405, which is showing strong results in their Phase 2 study for polycythemia vera (PV). In addition, their lead candidate bitopertin has received FDA alignment for accelerated approval in treating erythropoietic protoporphyria (EPP), and management is confident in their ability to meet the timeline for potential approval in 2027. With a diverse pipeline and positive feedback from treating physicians, Disc Medicine has the potential for long-term success and a potential price target of $120 per share.

Bears say

Disc Medicine is seeing promising results from its latest Phase 2 data for its lead drug selcodebart, showing a 56% major anemia response rate and a 72% overall response rate across patients with anemia from myelofibrosis. Furthermore, the company plans to hold an end-of-Phase 2 meeting with the FDA by year-end to discuss the path towards registration and has ongoing studies for additional indications. However, with a high valuation based on future sales projections and limited treatment options for myelofibrosis-associated anemia, there is considerable risk for this clinical-stage company.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.